

Myelodysplastisches Syndrom: Pathophysiologie, Diagnostik und Therapie

Syndrome myélodysplasique: physiopathologie, diagnostic et traitement

Literatur / Références

1. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. *British journal of haematology*. Oct 1992;82(2):358–367.
2. Parker JE, Mufti GJ. The myelodysplastic syndromes: a matter of life or death. *Acta haematologica*. 2004;111(1–2):78–99.
3. Tehranchi R, Fadeel B, Forsblom AM, et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. *Blood*. Feb 1 2003;101(3):1080–1086.
4. Albitar M, Manshouri T, Shen Y, et al. Myelodysplastic syndrome is not merely "preleukemia". *Blood*. Aug 1 2002;100(3):791–798.
5. Knipp S, Hildebrand B, Kundgen A, et al. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. *Cancer*. Jul 15 2007;110(2):345–352.
6. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. *Blood*. Feb 5 2009;113(6):1315–1325.
7. Schlegelberger B, Gohring G, Thol F, Heuser M. Update on cytogenetic and molecular changes in myelodysplastic syndromes. *Leukemia & lymphoma*. Apr 2012;53(4):525–536.
8. Fathi AT, Abdel-Wahab O. Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. *Advances in hematology*. 2012;2012:469592.
9. Damm F, Kosmider O, Gelsi-Boyer V, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. *Blood*. Apr 5 2012;119(14):3211–3218.
10. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. *The New England journal of medicine*. Jun 30 2011;364(26):2496–2506.
11. Mills KI, Kohlmann A, Williams PM, et al. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. *Blood*. Jul 30 2009;114(5):1063–1072.
12. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. *Blood*. Sep 20 2012;120(12):2454–2465.
13. Hellstrom-Lindberg E. Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents. *Hematology / the Education Program of the American Society of Hematology*. American Society of Hematology. Education Program. 2005:161–166.
14. Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. *Lancet*. Oct 13 2012;380(9850):1309–1316.
15. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. *The New England journal of medicine*. Oct 5 2006;355(14):1456–1465.
16. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *The lancet oncology*. Mar 2009;10(3):223–232.
17. Passweg JR, Giagounidis AA, Simcock M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. Jan 20 2011;29(3):303–309.
18. Sloan EM, Olnes MJ, Shenoy A, et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. Dec 10 2010;28(35):5166–5173.
19. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. *Blood*. Sep 1 2004;104(5):1266–1269.

20. Aviles A, Rubio ME, Gomez J, Medina ML, Gonzalez-Llaven J. Randomized study of danazol vs. placebo in myelodysplastic syndromes. *Archivos de investigacion medica*. Apr-Jun 1989;20(2):183–188.
21. Chabannon C, Molina L, Pegourie-Bandelier B, Bost M, Leger J, Hollard D. A review of 76 patients with myelodysplastic syndromes treated with danazol. *Cancer*. Jun 15 1994;73(12):3073–3080.
22. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. Feb 1 2010;28(4):562–569.
23. Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. *Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K.* Jul 2011;25(7):1147–1152.
24. Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. *Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation*. Jan 2009;15(1):30–38.
25. Oran B, Giralt S, Saliba R, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. *Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation*. Apr 2007;13(4):454–462.
26. de Witte T, Hagemeijer A, Suci S, et al. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. *Haematologica*. Oct 2010;95(10):1754–1761.
27. Field T, Perkins J, Huang Y, et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. *Bone marrow transplantation*. Feb 2010;45(2):255–260.
28. Kim DY, Lee JH, Park YH, et al. Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. *Bone marrow transplantation*. Mar 2012;47(3):374–379.
29. Gerds AT, Gooley TA, Estey EH, Appelbaum FR, Deeg HJ, Scott BL. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. *Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation*. Aug 2012;18(8):1211–1218.
30. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. *Blood*. Jul 15 2006;108(2):419–425.